Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zealand Pharma Ord Shs ZLDPF

Healthcare Biotechnology
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline... see more

Recent & Breaking News (PINL:ZLDPF)

Zealand Pharma to attend three U.S. healthcare conferences in December

GlobeNewswire November 29, 2017

Zealand increases its share capital as a consequence of exercise of employee warrants

GlobeNewswire November 20, 2017

Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide

GlobeNewswire November 14, 2017

Zealand Pharma: Interim report for the first nine months of 2017

GlobeNewswire November 8, 2017

Zealand Pharma will attend the Jefferies Healthcare Conference in London and the Bryan Garnier & Co Healthcare Conference in Paris, both in November

GlobeNewswire November 7, 2017

Zealand reports royalty revenue for the third quarter of 2017

GlobeNewswire November 2, 2017

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

GlobeNewswire October 24, 2017

Zealand increases its share capital as a consequence of exercise of employee warrants

GlobeNewswire September 22, 2017

Zealand increases its share capital as a consequence of exercise of employee warrants

GlobeNewswire September 1, 2017

Zealand grants new warrants under employee warrant program

GlobeNewswire August 25, 2017

Interim report for the first half of 2017

GlobeNewswire August 24, 2017

Phase 1 trials for two novel treatments of obesity and/or diabetes initiated by Zealand partner Boehringer Ingelheim

GlobeNewswire August 22, 2017

Akari Therapeutics Announces Appointment of David Horn Solomon as CEO

GlobeNewswire August 21, 2017

Completion of exercise in full of overallotment option of 15%

GlobeNewswire August 18, 2017

Overallotment option of 15% has been exercised

GlobeNewswire August 15, 2017

End of stabilization period

GlobeNewswire August 15, 2017

Completion of the initial public offering of American Depositary Shares and registration of capital increase

GlobeNewswire August 14, 2017

Zealand Pharma (Nasdaq: ZEAL) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire August 9, 2017

Zealand Pharma A/S prices its initial public offering of American Depositary Shares on The Nasdaq Global Select Market in the United States

GlobeNewswire August 8, 2017